2025
SJR Q3
JCR Q3 · 2,3
33 matched articles
SCIE
Journal detail
Current Drug Metabolism
- Publisher
- Bentham Science Publishers
- Country
- United Arab Emirates · Middle East
- Type
- journal
- ISSN
-
1389200218755453
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,492
- Quartile Q3
- H-Index 130
- Cites/doc 2,37
- Docs (3y) 225
- Cites (3y) 532
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,3
- 5Y JIF 2,5
- JCI 0,33
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Clinical Biochemistry Q3
- Pharmacology Q3
Areas
- Biochemistry, Genetics and Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Biochemistry & Molecular Biology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,492 | 2,3 | 2,5 | 0,33 | Q4 | 130 |
| 2024 | Q3 | Q3 | 0,522 | 1,8 | 2,6 | 0,34 | Q4 | 125 |
| 2023 | Q3 | Q3 | 0,453 | 2,1 | 2,9 | 0,35 | Q4 | 125 |
| 2022 | Q2 | Q3 | 0,574 | 2,3 | 3,4 | 0,44 | Q3 | 125 |
| 2021 | Q2 | Q3 | 0,62 | 3,4 | 3,7 | 0,44 | Q3 | 125 |
| 2020 | Q2 | Q2 | 0,667 | 3,7 | 3,6 | 0,47 | Q3 | 125 |
| 2019 | Q2 | Q2 | 0,65 | 3 | 3 | 0,54 | Q3 | 125 |
| 2018 | — | Q3 | — | 2,3 | 2,6 | 0,59 | Q3 | — |
| 2017 | Q2 | Q2 | 0,833 | 2,7 | 3 | 0,86 | Q2 | 125 |
| 2016 | Q2 | Q2 | 0,881 | 2,7 | 3,1 | — | — | 125 |
| 2015 | Q2 | Q2 | 0,977 | 2,8 | 3,2 | — | — | 125 |
| 2014 | Q2 | Q2 | 1,014 | 3 | 3,6 | — | — | 125 |
| 2013 | Q1 | Q1 | 1,138 | 3,5 | 4,2 | — | — | 125 |
| 2012 | Q1 | Q1 | 1,139 | 4,4 | 4,5 | — | — | 125 |
| 2011 | Q1 | Q1 | 0,993 | 5,1 | 4,9 | — | — | 125 |
| 2010 | Q1 | Q1 | 1,247 | 3,9 | 4,5 | — | — | 125 |
| 2009 | — | Q1 | — | 4 | 4,6 | — | — | — |
| 2008 | — | Q1 | — | 4,3 | 4,9 | — | — | — |
| 2007 | — | Q1 | — | 4,5 | 5,7 | — | — | — |
| 2006 | — | Q1 | — | 5,8 | — | — | — | — |
| 2005 | — | Q1 | — | 5,4 | — | — | — | — |
| 2004 | — | Q1 | — | 4,7 | — | — | — | — |
| 2003 | — | Q1 | — | 4,7 | — | — | — | — |
| 2002 | — | Q1 | — | 3 | — | — | — | — |
| 2001 | — | Q4 | — | 0,6 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q4 | 253/328 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 226/356 |
| 2024 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q4 | 264/320 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 244/352 |
| 2023 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q4 | 243/313 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 210/354 |
| 2022 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | Q4 | 235/285 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 200/278 |
| 2021 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 193/297 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 152/279 |
| 2020 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 161/295 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 125/276 |
| 2019 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 160/297 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 114/271 |
| 2018 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q3 | 200/299 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 158/267 |
| 2017 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | Q2 | 163/293 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 123/261 |
| 2016 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 151/290 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 116/257 |
| 2015 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 133/289 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 88/255 |
| 2014 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 125/290 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 82/255 |
| 2013 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 101/291 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 54/256 |
| 2012 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 68/290 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 36/261 |
| 2011 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 53/290 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 18/261 |
| 2010 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 93/286 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 43/252 |
| 2009 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 75/283 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 39/237 |
| 2008 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 68/275 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 30/219 |
| 2007 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 55/263 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 24/205 |
| 2006 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 40/262 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 13/199 |
| 2005 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 41/261 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 13/193 |
| 2004 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 49/261 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 18/187 |
| 2003 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q1 | — | 48/261 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 16/185 |
| 2002 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 85/266 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 37/188 |
| 2001 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q4 | — | 275/308 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 158/186 |